BioFocus DPI extends ISO certification to Leiden operations

Mechelen, Belgium; 28 November 2006 – Galapagos NV (Euronext & LSE: GLPG) announced today that its service division BioFocus DPI has extended its International Standards Organization’s ISO 9001:2000 certification to cover its Target Discovery operations in Leiden. BioFocus DPI first received certification for its Cambridge site in 2003. The extension to Leiden follows on an external audit performed by Lloyds Register of Quality Assurance (LRQA), a UKAS and Dutch RvA accredited quality certification body.

The scope of BioFocus DPI’s certification covers its provision of biological and chemical research for the pharmaceutical, biotechnology and agrochemical industries. ISO 9001 is an internationally accepted standard that represents good management practices and aims to ensure that organizations consistently deliver products or services that meet their clients’ quality requirements.

“This certification reflects our commitment to excellence in drug discovery and the professionalism and hard work of all our staff. We intend to build on our success in Leiden, as we strive to exceed our customers’ expectations,” said Chris Newton, Senior Vice President of BioFocus DPI.

About Galapagos

Galapagos is a publicly traded, genomics-based drug discovery company (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA, London AiM: GLPG) that has drug discovery programs based on proprietary, novel targets in bone and joint diseases - osteoarthritis, osteoporosis and rheumatoid arthritis. Galapagos offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies through its division BioFocus DPI, encompassing target discovery and drug discovery services through to delivery of pre-clinical candidates. In addition, BioFocus DPI provides adenoviral reagents for rapid identification and validation of novel drug targets and compound libraries for drug screening. Galapagos currently employs more than 330 people, including 144 PhDs, and operates facilities in seven countries, with global headquarters in Mechelen, Belgium. More information about Galapagos and BioFocus DPI can be found at www.glpg.com.

This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Contact Information

Chris Newton

Senior Vice President

BioFocus DPI

Contact via E-mail